Lulizumab pegol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Lulizumab pegol
Accession Number
DB15441
Type
Biotech
Groups
Investigational
Description

Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).

Synonyms
  • BMS-931699
Categories
UNII
LCT264LTYE
CAS number
1421830-13-8

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Lulizumab pegol.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Lulizumab pegol.
AbrilumabThe risk or severity of adverse effects can be increased when Abrilumab is combined with Lulizumab pegol.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Lulizumab pegol.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Lulizumab pegol.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Lulizumab pegol.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Lulizumab pegol.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Lulizumab pegol.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lulizumab pegol.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Lulizumab pegol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Lulizumab_pegol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedOtherHealthy Volunteers1
2CompletedOtherLupus1
2TerminatedTreatmentSjögren's Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 09:32 / Updated on May 21, 2019 12:43